

1. (Twice amended) A vaccine composition comprising: (a) an antigen, [; and antigenic compositions and combinations thereof;] (b) QS21 and (c) 3-De-O-acylated monophosphoryl lipid A (3D-MPL).

3. (Twice Amended) A vaccine composition as claimed in claim 1 capable of invoking a cytolytic T cell response in a mammal to the antigen [or antigenic composition].

12. (Twice amended) A process for making a vaccine composition according to claim 1 comprising admixing QS21 and 3D-MPL with an antigen [, antigenic composition or combination thereof].

15. (Twice amended) The composition as claimed in claim 14 capable of invoking a cytolytic T cell response in a mammal to an antigen [or antigenic composition].

Add the following claims.

19. (Added) The vaccine composition of claim 1 wherein the QS21 and the 3D-MPL synergistically enhance the immune response in an animal to the antigen.

20. (Added) The composition of claim 14 in which the QS21 and 3D-MPL synergistically enhance the immune response in an animal to an antigen.

21. (Added) A method of enhancing the immune response in an animal to an antigen which comprises administering to the animal (a) the antigen, (b) QS21, and (c) 3D-MPL.

22. (Added) The method of claim 21 in which the animal is a human.

23. (Added) The method of claim 21 wherein the QS21 and the 3D-MPL are administered at a ratio of QS21:3D-MPL of from 1:10 to 10:1.

24. (Added) The method of claim 21 wherein the ratio of QS21:3D-MPL is from 1:1 to 1:2.5.